Abstracts
Résumé
Contexte : Le tabagisme est élevé chez les personnes souffrant de schizophrénie ; certains patients réclament une aide au niveau de la médication qu’ils reçoivent afin de cesser de fumer. Objectif : Parmi les traitements pharmacologiques de la schizophrénie, la clozapine peut réduire la consommation de cigarettes. Les effets de la quétiapine, un autre antipsychotique atypique partageant plusieurs propriétés structurales et pharmacologiques avec la clozapine, ont été examinés chez un groupe de fumeurs atteints de schizophrénie dans une étude exploratoire. Méthode : Vingt-et-un individus fumeurs avec un diagnostic de schizophrénie, de trouble schizo-affectif ou de trouble schizophréniforme et recevant de la quétiapine ont été évalués à l’aide du questionnaire de Fagerström pour la dépendance à la nicotine. Ils ont de plus subi des analyses de monoxyde de carbone sanguin. Résultats : Le profil tabagique des sujets n’a pas été modifié significativement par l’administration de la quétiapine, malgré une amélioration de la symptomatologie psychiatrique. Conclusion : La quétiapine ne semble pas avoir d’effet significatif sur la consommation de cigarettes chez les fumeurs souffrant de schizophrénie.
Abstract
Context: Tobacco use is high among people suffering from schizophrenia ; certain patients demand help at the medication level they receive in order to stop smoking. Objective: Among the pharmacological treatment of schizophrenia, clozapine can reduce tobacco use. The effects of quetiapine, another atypical antipsychotic medication sharing several structural and pharmacological properties with clozapine, have been examined in a group of smokers with schizophrenia in an exploratory study. Method: Twenty-one smoking individuals with a diagnosis of schizophrenia, schizo-affective disorder or schizophreniform disorder and receiving quetiapine have been evaluated with the help of a questionnaire elaborated by Fagerström for nicotine addiction. They also were submitted to carbon monoxide blood analyses. Results: The tobacco profile of subjects was not modified significantly by the administration of quetiapine, despite an improvement of the psychiatric symptomatology. Conclusion: Quetiapine does not appear to have a significant effect on tobacco use in smokers suffering from schizophrenia.
Resumen
Contexto: El tabaquismo es elevado en las personas que sufren de esquizofrenia; algunos pacientes requieren ayuda a nivel de la medicación que reciben a fin de dejar de fumar. Objetivo: Entre los tratamientos farmacológicos de la esquizofrenia, la clozapina puede reducir el consumo de cigarrillos. Los efectos de la quetiapina, otro antipsicótico atípico que comparte varias propiedades estructurales y farmacológicas con la clozapina, han sido examinados en un estudio exploratorio de un grupo de fumadores que sufren de esquizofrenia. Método: Veintiún individuos fumadores diagnosticados con esquizofrenia, de trastorno esquizoafectivo o de trastorno esquizofreniforme, y que reciben quetiapina fueron evaluados con ayuda del cuestionario de Fagerström para la dependencia a la nicotina. Además se les realizaron análisis sanguíneos de monóxido de carbono. Resultados: la administración de quetiapina no modificó significativamente el perfil de tabaquismo de los pacientes, a pesar de la mejora de la sintomatología psiquiátrica. Conclusión: La quetiapina no parece tener efectos significativos en el consumo de cigarrillos en los fumadores que sufren de esquizofrenia.
Resumo
Contexto: O tabagismo é elevado nas pessoas que sofrem de esquizofrenia; alguns pacientes pedem a prescrição de remédios a fim de parar de fumar. Objetivo: Entre os tratamentos farmacológicos da esquizofrenia, a clozapina pode reduzir o consumo de cigarro. Os efeitos da quetiapina, um outro antipsicótico atípico que possui várias propriedades estruturais e farmacológicas semelhantes às da clozapina, foram examinados em um grupo de fumantes que sofrem de esquizofrenia em um estudo exploratório. Método: 21 indivíduos fumantes com um diagnóstico de esquizofrenia, transtorno esquizoafetivo ou de transtorno esquizofreniforme e que recebem quetiapina foram avaliados com a ajuda do questionário de Fageström para a dependência à nicotina. Além disto, eles passaram por análises de monóxido de carbono sangüíneo. Resultados: o perfil tabagístico das pessoas não foi modificado significativamente pela administração da quetiapina, apesar da melhoria da sintomatologia psiquiátrica. Conclusão: A quetiapina não parece ter efeito significativo no consumo de cigarros nos fumantes que sofrem de esquizofrenia.
Appendices
Références
- Addington, D., Addington, J., Schissel, B., 1990, A depression rating scale for schizophrenics, Schizophrenia Research, 3, 247-251.
- Adler, L. E., Olincy, A., Waldo, M., Harris, J. G., Griffith, J., Stevens, K., Flach, K., Nagamoto, H., Bickford, P., Leonard, S., Freedman, R., 1998, Schizophrenia, sensory gating and nicotinic receptors, Schizophrenia Bulletin, 24, 189-202.
- American Psychiatric Association, 2000, Diagnostic and Statistical Manual of Mental Disorders, 4th ed., Text revision, American Psychiatric Association, Washington DC.
- Barnes, T. R., 1989, A rating scale for drug-induced akathisia, British Journal of Psychiatry, 154, 672-676.
- Brauer, L. H., Cramblett, M. J., Paxton, D. A., Rose, J. E., 2001, Haloperidol reduces smoking of both nicotine-containing and denicotinized cigarettes, Psychopharmacology, 159, 31-37.
- Brown, E. S., Netjek, V. A., Perantie, D. C., Rajan Thomas, N., Rush, A. J., 2003, Cocaine and amphetamine use in patients with psychiatric illness : a randomized trial of typical antipsychotic continuation or discontinuation, Journal of Clinical Psychopharmacology, 23, 384-388.
- Cheer, S. M., Wagstaff, A. J., 2004, Quetiapine. A review of its use in the management of schizophrenia, CNS Drugs, 18, 173-199.
- Chouinard, G., Ross-Chouinard, A., 1980, The extrapyramidal symptom rating scale, Canadian Journal of Neurological Sciences, 7, 233.
- Dawe, S., Gerada, C., Russell, M. A., Gray, J. A., 1995, Nicotine intake in smokers increase following a single dose of haloperidol, Psychopharmacology, 117, 110-115.
- De Leon J., Diaz F. J., Josiassen R. C., Cooper T. B., Simpson G. M., 2005, Does clozapine decrease smoking ?, Progress In Neuro-Psychopharmacology and Biological Psychiatry, 29, 757-762.
- De Leon, J., Tracy, J., Mccann, E., Mcgrory, A., Diaz, F. J., 2002, Schizophrenia and tobacco smoking : A replication study in another US psychiatric hospital, Schizophrenia Research, 56, 55-65.
- De Leon, J., Dadvand, M., Canuso, C., White, A. O., Stanilla, J. K., Simpson, G. M., 1995, Schizophrenia and smoking : An epidemiological survey in a state hospital, American Journal of Psychiatry, 152, 453-455.
- Drake, R. E., Xie, H., Mchugo, G. J., Green, A. I., 2000, The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia, Schizophrenia Bulletin, 26, 441-449.
- Fagerström, K. O., Schneider, N. G., 1989, Measuring nicotine dependence : A review of the Fagerström Tolerance Questionnaire, Journal of Behavioural Medicine, 12, 159-182.
- Gefvert, O., Lundberg, T., Wieselgren, I. M., Bergstrom, M., Langstrom, B., Wiesel, F., Lindstrom, L., 2001, D2 and 5-HT2a receptor occupancy of different doses of quetiapine in schizophrenia : A PET study, European Neuropsychopharmacology, 11, 105-110.
- George, T. P., Sernyak, M. J., Ziedonis, D. M., Woods, S. W., 1995, Effects of clozapine on smoking in chronic schizophrenic outpatients, Journal of Clinical Psychiatry, 56, 344-346.
- Glassman, A. H., 1993, Cigarette smoking : Implications for psychiatric illness, American Journal of Psychiatry, 150, 546-553.
- Goff, D. C., Henderson, D. C., Amico, E., 1992, Cigarette smoking in schizophrenia : Relationship to psychopathology and medication side effects, American Journal of Psychiatry, 149, 1189-1194.
- Hughes, J. R., Hatsukami, D. K., Mitchell, J. E., Dahlgren, L. A., 1986, Prevalence of smoking among psychiatric outpatients, American Journal of Psychiatry, 143, 993-997.
- Kay, S. R., Fiszbein, A., Opler, L. A., 1987, The positive and negative syndrome scale for schizophrenia, Schizophrenia Bulletin, 13, 261-276.
- Martin, L. F., Kem, W. R., Freedman, R., 2004, Alpha-7 nicotinic receptor agonists : potential new candidates for the treatment of schizophrenia, Psychopharmacology, 174, 54-64.
- Mcevoy, J. P., Freudenreich, O., Wilson, W. H., 1999, Smoking and therapeutic response to clozapine in patients with schizophrenia, Biological Psychiatry, 46, 125-129.
- McEvoy, J. P., Freudenreich, O., Mcgee, M., Vanderzwaag, C., Levin, E., Rose, J., 1995a, Clozapine decreases smoking in patients with chronic schizophrenia, Biological Psychiatry, 37, 550-552.
- McEvoy, J. P., Freudenreich, O., Levin, E., Rose, J. E., 1995b, Haloperidol increases smoking in patients with schizophrenia, Psychopharmacology, 119, 124-126.
- Procyshyn, R. M., Tse, G., Sin, O., Flynn, S., 2002, Concomitant clozapine reduces smoking in patients treated with risperidone, European Neuropsychopharmacology, 12, 7780.
- Procyshyn, R. M., Ihsan, N., Thompson, D., 2001, A comparison of smoking behaviours between patients treated with clozapine and depot neuroleptics, International Clinical Psychopharmacology, 16, 291-294.
- Sadock, B. J., Sadock, V. A., 2003, Kaplan and Sadock’s Synopsis of Psychiatry, Behavioral Sciences, Clinical Psychiatry, 9th ed., Lippincott Williams and Wilkins, Philadelphia.
- Seeman, P., 2002, Atypical antipsychotics : Mechanism of action, Canadian Journal of Psychiatry, 47, 27-38.
- Sherr, J. D., Myers, C., Avila, M. T., Elliott, A., Blaxton, T. A., Thaker, G. K., 2002, The effects of nicotine on specific eye tracking measures in schizophrenia, Biological Psychiatry, 52, 721-728.
- Simosky, J. K., Stevens, K. E., Adler, L. E., Freedman, R., 2003, Clozapine improves deficient inhibitory auditory processing in DBA/2 mice, via a nicotinic cholinergic mechanism, Psychopharmacology, 165, 386-396.
- Steinberg, M. L., Williams, J. M., Steinberg, H. R., Krejci, J. A., Ziedonis, D. M., 2005, Applicability of the Fagerstrom test for nicotine dependence in smokers with schizophrenia, Addictive Behaviors, 30, 49-59.